Symbols / SAVA $2.38 +12.26%
SAVA Chart
About
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 114.97M |
| Enterprise Value | -5.12M | Income | -106.03M | Sales | — |
| Book/sh | 1.69 | Cash/sh | 2.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | -1.34 | PEG | — |
| P/S | — | P/B | 1.41 | P/C | — |
| EV/EBITDA | 0.07 | EV/Sales | — | Quick Ratio | 2.23 |
| Current Ratio | 2.27 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.22 | EPS next Y | -1.77 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -24.80% |
| ROE | -85.44% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 48.31M |
| Shs Float | 42.98M | Short Float | 14.89% | Short Ratio | 9.40 |
| Short Interest | — | 52W High | 4.98 | 52W Low | 1.15 |
| Beta | -0.84 | Avg Volume | 784.20K | Volume | 2.06M |
| Target Price | $8.00 | Recom | None | Prev Close | $2.12 |
| Price | $2.38 | Change | 12.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.38
Latest analyst target
3. DCF / Fair value
$6.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.38
Low
$8.00
High
$8.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-06 | init | LUCID CAPITAL MARKETS | — → Buy | $8 |
| 2025-03-25 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-03-04 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-26 | down | HC Wainwright & Co. | Buy → Neutral | $116 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $116 |
| 2024-10-08 | up | HC Wainwright & Co. | Neutral → Buy | $116 |
| 2024-08-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-08 | reit | Rodman & Renshaw | Buy → Buy | $107 |
| 2024-07-19 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-07-01 | down | Jones Trading | Buy → Hold | — |
| 2024-07-01 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-05-17 | main | HC Wainwright & Co. | Buy → Buy | $131 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-07-06 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-05-11 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-05-09 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2023-03-06 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2023-01-24 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2022-08-11 | main | B. Riley Securities | — → Buy | $44 |
- Biotech Cassava will pay $31.25M to end investor lawsuit from 2021 - Stock Titan ue, 23 Dec 2025 08
- SAVA Stock Price, Quote & Chart | CASSAVA SCIENCES INC (NASDAQ:SAVA) - ChartMill ue, 10 Mar 2026 07
- Cassava Sciences (NASDAQ:SAVA) Stock Rating Upgraded by Wall Street Zen - MarketBeat Sun, 08 Mar 2026 08
- Cassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program Withdrawal - Yahoo Finance Sat, 27 Sep 2025 07
- $SAVA stock is down 23% today. Here's what we see in our data. - Quiver Quantitative Fri, 19 Dec 2025 08
- Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Fri, 19 Dec 2025 08
- Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Stocktwits Fri, 19 Dec 2025 08
- Cassava Sciences (SAVA) Soars 18% After CEO's Substantial Investment - FinancialContent ue, 23 Sep 2025 07
- Cassava Sciences stock up as CEO buys shares (SAVA:NASDAQ) - Seeking Alpha Fri, 21 Nov 2025 08
- Cassava Pops After CEO Buys 150,000 Shares - TradingView ue, 25 Nov 2025 08
- $SAVA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 08
- Cassava Boss Buys Big As Stock Collapses - Yahoo Finance ue, 23 Sep 2025 07
- Alzheimer’s drug trial data reveal blood test limits and safety clues - Stock Titan ue, 13 Jan 2026 08
- Biggest stock movers Tuesday: SAVA, CLSK, PLUG, and more - Seeking Alpha ue, 23 Sep 2025 07
- Cassava Sciences (NASDAQ:SAVA) CEO Acquires $108,335.32 in Stock - MarketBeat Mon, 22 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8600 | 24940 | — | Purchase at price 2.90 per share. | ANDERSON ROBERT EUGENE JR | Director | — | 2025-11-24 00:00:00 | D |
| 1 | 150000 | 414000 | — | Purchase at price 2.76 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-11-20 00:00:00 | I |
| 2 | 73385 | 201809 | — | Purchase at price 2.75 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-11-19 00:00:00 | I |
| 3 | 13725 | 39940 | — | Purchase at price 2.91 per share. | COOK ROBERT CHRISTOPHER | Chief Operating Officer | — | 2025-09-30 00:00:00 | D |
| 4 | 7172 | 16352 | — | Purchase at price 2.28 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-09-22 00:00:00 | I |
| 5 | 237941 | 534743 | — | Purchase at price 2.13 - 2.29 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-09-19 00:00:00 | I |
| 6 | 50000 | 59000 | — | Conversion of Exercise of derivative security at price 1.18 per share. | SCHOEN ERIC J. | Chief Financial Officer | — | 2024-11-29 00:00:00 | D |
| 7 | 61800 | 238468 | — | Sale at price 3.82 - 3.86 per share. | SCHOEN ERIC J. | Chief Financial Officer | — | 2024-11-29 00:00:00 | D/I |
| 8 | 4000 | 15480 | — | Sale at price 3.87 per share. | KUPIEC JAMES WILLIAM | Officer | — | 2024-11-29 00:00:00 | D |
| 9 | 5000 | — | — | Stock Gift at price 0.00 per share. | ROBERTSON SANFORD R | Director | — | 2024-05-16 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -95.19M | -249.33M | -105.80M | -80.18M |
| TotalUnusualItems | 108.18M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 108.18M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -90.97M | -24.34M | -97.22M | -76.25M |
| ReconciledDepreciation | 936.00K | 1.13M | 1.53M | 1.30M |
| EBITDA | -95.19M | -141.15M | -105.80M | -80.18M |
| EBIT | -96.13M | -142.28M | -107.33M | -81.48M |
| NetInterestIncome | 4.62M | 8.51M | 7.83M | 2.78M |
| InterestIncome | 4.62M | 8.51M | 7.83M | 2.78M |
| NormalizedIncome | -90.97M | -132.53M | -97.22M | -76.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -90.97M | -24.34M | -97.22M | -76.25M |
| TotalExpenses | 96.13M | 142.28M | 107.33M | 81.48M |
| TotalOperatingIncomeAsReported | -95.39M | -141.45M | -105.96M | -80.02M |
| DilutedAverageShares | 48.30M | 46.60M | 41.93M | 40.20M |
| BasicAverageShares | 48.30M | 46.33M | 41.93M | 40.20M |
| DilutedEPS | -1.88 | -1.46 | -2.32 | -1.90 |
| BasicEPS | -1.88 | -0.53 | -2.32 | -1.90 |
| DilutedNIAvailtoComStockholders | -90.97M | -68.14M | -97.22M | -76.25M |
| AverageDilutionEarnings | 0.00 | -43.79M | 0.00 | 0.00 |
| NetIncomeCommonStockholders | -90.97M | -24.34M | -97.22M | -76.25M |
| NetIncome | -90.97M | -24.34M | -97.22M | -76.25M |
| NetIncomeIncludingNoncontrollingInterests | -90.97M | -24.34M | -97.22M | -76.25M |
| NetIncomeContinuousOperations | -90.97M | -24.34M | -97.22M | -76.25M |
| PretaxIncome | -90.97M | -24.34M | -97.22M | -76.25M |
| OtherIncomeExpense | 533.00K | 109.43M | 2.28M | 2.46M |
| OtherNonOperatingIncomeExpenses | 533.00K | 1.24M | 2.28M | 2.46M |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfPPE | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | 108.18M | |||
| NetNonOperatingInterestIncomeExpense | 4.62M | 8.51M | 7.83M | 2.78M |
| InterestIncomeNonOperating | 4.62M | 8.51M | 7.83M | 2.78M |
| OperatingIncome | -96.13M | -142.28M | -107.33M | -81.48M |
| OperatingExpense | 96.13M | 142.28M | 107.33M | 81.48M |
| OtherOperatingExpenses | 736.00K | 833.00K | 1.38M | 1.46M |
| ResearchAndDevelopment | 26.59M | 69.64M | 89.42M | 68.03M |
| SellingGeneralAndAdministration | 68.80M | 71.81M | 16.53M | 11.99M |
| GeneralAndAdministrativeExpense | 68.80M | 71.81M | 16.53M | 11.99M |
| OtherGandA | 68.80M | 71.81M | 16.53M | 11.99M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 48.31M | 48.20M | 42.24M | 41.74M |
| ShareIssued | 48.31M | 48.20M | 42.24M | 41.74M |
| TotalDebt | 0.00 | 139.00K | 236.00K | |
| TangibleBookValue | 74.40M | 145.70M | 137.29M | 226.92M |
| InvestedCapital | 74.40M | 145.70M | 137.47M | 227.54M |
| WorkingCapital | 53.88M | 124.78M | 115.44M | 204.16M |
| NetTangibleAssets | 74.40M | 145.70M | 137.29M | 226.92M |
| CapitalLeaseObligations | 0.00 | 139.00K | 236.00K | |
| CommonStockEquity | 74.40M | 145.70M | 137.47M | 227.54M |
| TotalCapitalization | 74.40M | 145.70M | 137.47M | 227.54M |
| TotalEquityGrossMinorityInterest | 74.40M | 145.70M | 137.47M | 227.54M |
| StockholdersEquity | 74.40M | 145.70M | 137.47M | 227.54M |
| RetainedEarnings | -496.08M | -405.11M | -380.77M | -283.55M |
| AdditionalPaidInCapital | 570.44M | 550.77M | 518.20M | 511.05M |
| CapitalStock | 48.00K | 48.00K | 42.00K | 42.00K |
| CommonStock | 48.00K | 48.00K | 42.00K | 42.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 43.95M | 11.83M | 14.20M | 7.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 118.00K | 79.00K | 0.00 | 232.00K |
| OtherNonCurrentLiabilities | 118.00K | 79.00K | 197.00K | 194.00K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 35.00K | 139.00K | |
| LongTermCapitalLeaseObligation | 0.00 | 35.00K | 139.00K | |
| CurrentLiabilities | 43.83M | 11.75M | 14.20M | 7.06M |
| OtherCurrentLiabilities | 198.00K | 299.00K | 385.00K | 492.00K |
| CurrentDebtAndCapitalLeaseObligation | 104.00K | 97.00K | ||
| CurrentCapitalLeaseObligation | 0.00 | 104.00K | 97.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.62M | 1.36M | 200.00K | 170.00K |
| PayablesAndAccruedExpenses | 42.01M | 10.09M | 13.61M | 6.30M |
| CurrentAccruedExpenses | 364.00K | 2.44M | 3.04M | 2.28M |
| Payables | 41.65M | 7.65M | 10.57M | 4.02M |
| AccountsPayable | 41.65M | 7.65M | 10.57M | 4.02M |
| TotalAssets | 118.36M | 157.53M | 151.66M | 234.83M |
| TotalNonCurrentAssets | 20.65M | 21.00M | 22.03M | 23.61M |
| OtherNonCurrentAssets | 399.00K | |||
| GoodwillAndOtherIntangibleAssets | 37.00K | 176.00K | 622.00K | 1.07M |
| OtherIntangibleAssets | 37.00K | 176.00K | 622.00K | 1.07M |
| NetPPE | 20.65M | 21.00M | 21.85M | 22.99M |
| AccumulatedDepreciation | -4.14M | -3.24M | -2.28M | -1.20M |
| GrossPPE | 24.79M | 24.24M | 24.14M | 24.19M |
| Leases | 3.47M | 3.06M | 3.06M | 3.02M |
| ConstructionInProgress | 25.00K | 55.00K | 0.00 | 13.00K |
| OtherProperties | 687.00K | 531.00K | 494.00K | 470.00K |
| MachineryFurnitureEquipment | 891.00K | 875.00K | 868.00K | 851.00K |
| BuildingsAndImprovements | 15.98M | 15.98M | 15.98M | 16.10M |
| LandAndImprovements | 3.73M | 3.73M | 3.73M | 3.73M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 97.71M | 136.53M | 129.63M | 211.23M |
| OtherCurrentAssets | 64.00K | 38.00K | 287.00K | 160.00K |
| PrepaidAssets | 2.02M | 6.97M | 7.25M | 10.05M |
| Receivables | 120.00K | 947.00K | 962.00K | 0.00 |
| AccruedInterestReceivable | 120.00K | 947.00K | 962.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 95.50M | 128.57M | 121.14M | 201.01M |
| CashAndCashEquivalents | 95.50M | 128.57M | 121.14M | 201.01M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -32.83M | -117.03M | -82.44M | -80.23M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 47.33M | 189.82M |
| CapitalExpenditure | -581.00K | -103.00K | -414.00K | -2.71M |
| EndCashPosition | 95.50M | 128.57M | 121.14M | 201.01M |
| BeginningCashPosition | 128.57M | 121.14M | 201.01M | 233.44M |
| ChangesInCash | -33.07M | 7.44M | -79.88M | -32.42M |
| FinancingCashFlow | -239.00K | 124.47M | 2.56M | 47.80M |
| CashFlowFromContinuingFinancingActivities | -239.00K | 124.47M | 2.56M | 47.80M |
| NetOtherFinancingCharges | -329.00K | |||
| ProceedsFromStockOptionExercised | 90.00K | 124.47M | 2.56M | 475.00K |
| NetCommonStockIssuance | 0.00 | 0.00 | 47.33M | 189.82M |
| CommonStockIssuance | 0.00 | 0.00 | 47.33M | 189.82M |
| InvestingCashFlow | -581.00K | -103.00K | -414.00K | -2.71M |
| CashFlowFromContinuingInvestingActivities | -581.00K | -103.00K | -414.00K | -2.71M |
| NetPPEPurchaseAndSale | -581.00K | -103.00K | -414.00K | -2.71M |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -581.00K | -103.00K | -414.00K | -2.71M |
| OperatingCashFlow | -32.25M | -116.93M | -82.03M | -77.51M |
| CashFlowFromContinuingOperatingActivities | -32.25M | -116.93M | -82.03M | -77.51M |
| ChangeInWorkingCapital | 38.20M | -1.83M | 9.08M | -4.63M |
| ChangeInOtherWorkingCapital | 268.00K | 1.16M | 13.00K | -1.72M |
| ChangeInOtherCurrentLiabilities | -62.00K | -7.00K | -304.00K | -136.00K |
| ChangeInPayablesAndAccruedExpense | 31.92M | -3.52M | 7.65M | -3.97M |
| ChangeInAccruedExpense | -2.08M | -597.00K | 757.00K | -523.00K |
| ChangeInPayable | 33.99M | -2.92M | 6.90M | -3.45M |
| ChangeInAccountPayable | 33.99M | -2.92M | 6.90M | -3.45M |
| ChangeInPrepaidAssets | 6.08M | 539.00K | 1.71M | 1.19M |
| StockBasedCompensation | 19.58M | 16.29M | 4.59M | 2.07M |
| DepreciationAmortizationDepletion | 936.00K | 1.13M | 1.53M | 1.30M |
| DepreciationAndAmortization | 936.00K | 1.13M | 1.53M | 1.30M |
| AmortizationCashFlow | 33.00K | 180.00K | 446.00K | 497.00K |
| AmortizationOfIntangibles | 33.00K | 180.00K | 446.00K | 497.00K |
| Depreciation | 903.00K | 952.00K | 1.08M | 804.00K |
| OperatingGainsLosses | -108.18M | |||
| GainLossOnInvestmentSecurities | -108.18M | |||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -90.97M | -24.34M | -97.22M | -76.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SAVA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|